intermittent ADT

Is Intermittent Androgen Suppression Becoming the New Standard in Recurrent Prostate Cancer?

Recent data presented at the 2011 Genitourinary Cancers Symposium supports the growing consensus that intermittent androgen suppression (IADT) is no less effective than continuous androgen suppression at treating men with prostate cancer that recurs after radiotherapy. Lead investigator, Laurence Klotz, MD, chief of urology, Sunnybrook Health Sciences Center, and professor of surgery at the University [...]

By |2017-10-19T10:52:37-04:00May 26th, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Radiotherapy, Uncategorized, Understanding APC|1 Comment
Read More

A phase III Trial Comparing Intermittent versus Continuous ADT for Men with PSA Progression after Radiotherapy

In prior studies with men who have had a PSA recurrence after radiotherapy (RT), intermittent androgen suppression (IAS) has been suggested to improve quality of life (QoL) but effects on survival are unknown. The researchers performed an inter-group randomized phase III trial, which compared IAS vs continuous androgen deprivation (CAD) to test overall survival (OS) [...]

By |2011-02-22T11:11:47-05:00February 22nd, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Radiotherapy, Uncategorized, Understanding APC|0 Comments
Read More

Changing ADT in the Treatment of Prostate Cancer – Are We Using It Correctly?

Patient advocates have long raised the question about the wisdom in using hormone therapy for extended periods of time. The introduction of intermittent scheduling of hormone therapy (ADT) has become more acceptable thanks to the questions raised by the community and the support of some oncologists who have been willing to think out of the [...]

By |2020-02-04T08:21:38-05:00January 21st, 2011|Advanced Prostate Cancer, Drugs & Treatments, General Information, Hormone Therapy, Prostate Ponderings, Uncategorized, Understanding APC|1 Comment
Read More

Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men with Biochemical Recurrence of Prostate Cancer

It has been clearly shown that androgen deprivation therapy (ADT) for the treatment of prostate cancer leads to loss of bone mineral density (BMD) and increased fracture risk. More importantly, loss of BMD shortens survival time. (see my post of December 27, 2009 “On the Horizon – Dasatinib A Drug to Inhibit the growth of [...]

By |2017-10-19T10:54:01-04:00May 26th, 2010|Advanced Prostate Cancer, Bone Mineral Density, Clinical Trials, Clinical Trials, Hormone Therapy, Uncategorized, Understanding APC|0 Comments
Read More

Continious ADT vs Intermittent – There is a Winner From This Trial

One of the unsettled debates in our advanced prostate cancer world surrounds the issue of continuous vs. intermittent hormone therapy (IHT). Traditionally, hormone therapy was continuous, or once you started you never stopped the treatment. As many of us know, hormone therapy is notorious for damaging the quality of life. Hot flashes, loss of libido, [...]

By |2017-10-19T10:55:48-04:00March 31st, 2009|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, How We Live, Uncategorized, Understanding APC|0 Comments
Read More
Go to Top